iBio, Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.www.ibioinc.com
15
MENTIONS
4
EPISODES
4
PODCASTS
Search complete. 15 mentions across 4 episodes found for "iBio, Inc.".
Oct 29, 2026
Ehsan RahimyGUEST
So what about those patients? And that's what's generated quite a bit of excitement with modulators.
Ehsan RahimyGUEST
And so Merck had acquired iBio.
Ehsan RahimyGUEST
They had Remigremib.
Ehsan RahimyGUEST
We saw the results of the Brunello trial, which looked promising.
13 MINS LATER
Ehsan RahimyGUEST
You know, average phase three clinical trial in this country costs anywhere between 20 to 50 million dollars to run.
Ehsan RahimyGUEST
You know, a number of these companies that we've spoken of, they're very small companies.
Ehsan RahimyGUEST
We have big pharma in the room, right? Merck acquired iBio.
Ehsan RahimyGUEST
There's Regeneron.
Scott KrzywonosHOST
Just going over some of the numbers quickly, then we can get into what the implications are.
Scott KrzywonosHOST
Merck acquired iBio.
Scott KrzywonosHOST
This was in 2024.
Scott KrzywonosHOST
That is a valuation of up to $3 billion, which kind of looks like a deal to me right now, even though it's a lot of money.
Scott KrzywonosHOST
What are you seeing now that there are these larger pharma companies, the kind of companies that advertise during an NFL game? What are you seeing now that that kind of institutional resource exists in the field?
John KitchensHOST
Well, I think in some cases, in many cases, you're seeing that they are continuing to invest in the same teams and the same people that got them there.
John KitchensHOST
You know, so you look, I mean... iBio, it's hard to question anything Tony Ademus does and the people around him, John Printer, Bryce Miller, Aaron Henry, all of the people that really went into the science side of iBio.
John KitchensHOST
I remember when they bought iBio, people thought, oh my gosh, up to $3 billion.
Maya PatelHOST
It reads out before year-end, and RBC said in August that approval gets harder without two positive non-inferiority trials.
Alex MercerHOST
In our October 11th week in review, after iBio's Remigramig, now Merckx, met non-inferiority to monthly ranibizumab in Brunello, we argued that matching an aging comparator may not get paid.
Maya PatelHOST
That comparator problem is spreading.
Maya PatelHOST
Aflibirsept 2 mg, the standard in Daybreak and Lugano, already has a second U.S. biosimilar, Biocon's Yesophili, launched August 3rd, and Sandoz and Formicon hold settlement windows this quarter or earlier.
Bob SullivanHOST
I'll let you introduce him, Mike.
CostaHOST
CEO, chief scientific officer, IBIO Incorporated, strangely enough, their ticker symbol IBIO.
Bob SullivanHOST
I- IBIO, uh, interesting, I th- had forgotten, 'cause I, you know, I, I kinda keep my finger on the pulse of these things.
Bob SullivanHOST
You guys, y- you're with, um, uh, Pathenx, weren't you? With, with the w- w- it, it-
Martin BrunnerGUEST
Pathenx before, yep.
speaker_3UNKNOWN
[laughs]
Bob SullivanHOST
Well, you s- you sure did.
Bob SullivanHOST
[laughs] Um, let's talk for the folks that didn't get a chance to see you last time, give us an overview of IBIO and what you guys are doing and w- and, and, and, and the therapies and such.